Author details

Full Name

Angelika Eggert

Affiliation

ORCID

Career Start Year

1991

Papers

258

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36854071	Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.	J Clin Oncol	2023
35687182	Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma.	J Cancer Res Clin Oncol	2023
36134454	Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study.	Haematologica	2023
36416169	X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.	EMBO Molecular Medicine	2023
37868040	Mutational topography reflects clinical neuroblastoma heterogeneity.	Cell Genom	2023
37402719	Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN.	Nat Commun	2023
37142849	Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells.	Nat Genet	2023
37017830	Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.		2023
36875143	Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease.		2023
37444475	Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.	Cancers (Basel)	2023
36476835	Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.	Oncogene	2023
36542877	Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.	Eur J Cancer	2023
34606174	Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma.	Pediatr Blood Cancer	2022
36354709	Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.	Current Oncology	2022
35879366	Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.	Nature Communications	2022
35689207	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.	Mol Cancer	2022
35565208	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics.	Cancers	2022
35613412	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion.	JCO Precis Oncol	2022
36700232	Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.		2022
33661164	Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein.	Journal of Pediatric Hematology/Oncology	2022
32649454	A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPENâ¿¿, COGâ¿¿â¿¿, and GPOHâ¿¿â¿¿â¿¿.	Annals of Surgery	2022
34980229	Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.	J Exp Clin Cancer Res	2022
35247920	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.	Clinical Cancer Research	2022
34808385	Yoga, Meditation and Mindfulness in pediatric oncology - A review of literature.	Complementary Therapies in Medicine	2021
33801448	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.	Cancers	2021
34285106	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.	Journal for ImmunoTherapy of Cancer	2021
33731935	Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine.	Nature	2021
33572828	Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma.	Children	2021
33947691	ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.	Clinical Cancer Research	2021
34267756	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.	Frontiers in Immunology	2021
34202325	Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging.	Cancers	2021
34199532	Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the <i>ATM</i> Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma.	Children (Basel)	2021
33720495	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG).	Pediatr Blood Cancer	2021
33874968	External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial.	Radiation Oncology	2021
33768209	Combined inhibition of Aurora-A and ATR kinase results in regression of -amplified neuroblastoma.	Nature Cancer	2021
34192988	Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.	Journal of Enzyme Inhibition and Medicinal Chemistry	2021
33919815	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria.	Cancers (Basel)	2021
33918978	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.	Cancers (Basel)	2021
33098344	Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease-A single center experience.	Pediatric Transplantation	2021
33040053	Development of an Integrative Care Program in a Pediatric Oncology Unit.	Complementary Medicine Research	2021
33248249	Perception of integrative care in paediatric oncology-perspectives of parents and patients.	Complementary Therapies in Medicine	2021
33300099	Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NBÂ 2004.	Strahlentherapie und Onkologie	2021
33284994	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.	International Journal of Cancer	2021
34735429	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.	PLoS Computational Biology	2021
34442335	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.	J Pers Med	2021
34379779	Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections.	Journal of the Pediatric Infectious Diseases Society	2021
34771652	Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis.	Cancers	2021
34654445	Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.	J Exp Clin Cancer Res	2021
34373263	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.	Cancer Discov	2021
34815394	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.	Nat Commun	2021